Oxinas Partners Wealth Management LLC Sells 879 Shares of Pfizer Inc. (NYSE:PFE)

Oxinas Partners Wealth Management LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 8.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,354 shares of the biopharmaceutical company’s stock after selling 879 shares during the period. Oxinas Partners Wealth Management LLC’s holdings in Pfizer were worth $260,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Clifford Swan Investment Counsel LLC grew its position in Pfizer by 4.7% in the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after purchasing an additional 18,611 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its position in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after buying an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC acquired a new stake in Pfizer during the fourth quarter worth about $255,000. Cantor Fitzgerald Investment Advisors L.P. bought a new position in Pfizer during the fourth quarter valued at about $16,166,000. Finally, KLCM Advisors Inc. raised its holdings in Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after acquiring an additional 74,487 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE PFE traded down $0.39 during mid-day trading on Tuesday, hitting $27.83. 21,710,519 shares of the stock were exchanged, compared to its average volume of 40,642,027. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80. The stock’s fifty day simple moving average is $27.93 and its two-hundred day simple moving average is $27.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The company has a market cap of $157.70 billion, a P/E ratio of -464.76, a PEG ratio of 1.10 and a beta of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s revenue was down 19.5% on a year-over-year basis. During the same period last year, the firm posted $1.23 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, June 26th. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $35.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.